Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $6.19 billion. The enterprise value is $4.86 billion.
| Market Cap | 6.19B |
| Enterprise Value | 4.86B |
Important Dates
The next confirmed earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 96.67 million shares outstanding. The number of shares has increased by 4.16% in one year.
| Current Share Class | 96.67M |
| Shares Outstanding | 96.67M |
| Shares Change (YoY) | +4.16% |
| Shares Change (QoQ) | +9.01% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 97.97% |
| Float | 90.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 3,585.16 |
| PB Ratio | 4.62 |
| P/TBV Ratio | 4.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.79, with a Debt / Equity ratio of 0.01.
| Current Ratio | 27.79 |
| Quick Ratio | 27.53 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.53% and return on invested capital (ROIC) is -25.07%.
| Return on Equity (ROE) | -37.53% |
| Return on Assets (ROA) | -24.22% |
| Return on Invested Capital (ROIC) | -25.07% |
| Return on Capital Employed (ROCE) | -30.64% |
| Weighted Average Cost of Capital (WACC) | 7.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 370 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.98M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +109.87% in the last 52 weeks. The beta is 0.61, so XENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +109.87% |
| 50-Day Moving Average | 59.55 |
| 200-Day Moving Average | 50.36 |
| Relative Strength Index (RSI) | 52.15 |
| Average Volume (20 Days) | 1,119,551 |
Short Selling Information
The latest short interest is 6.34 million, so 6.56% of the outstanding shares have been sold short.
| Short Interest | 6.34M |
| Short Previous Month | 6.26M |
| Short % of Shares Out | 6.56% |
| Short % of Float | 6.98% |
| Short Ratio (days to cover) | 3.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | -328.25M |
| Operating Income | -412.66M |
| Pretax Income | -385.15M |
| Net Income | -383.17M |
| EBITDA | -410.19M |
| EBIT | -412.66M |
| Earnings Per Share (EPS) | -$4.71 |
Balance Sheet
The company has $1.09 billion in cash and $7.49 million in debt, with a net cash position of $1.33 billion or $13.78 per share.
| Cash & Cash Equivalents | 1.09B |
| Total Debt | 7.49M |
| Net Cash | 1.33B |
| Net Cash Per Share | $13.78 |
| Equity (Book Value) | 1.34B |
| Book Value Per Share | 13.85 |
| Working Capital | 1.07B |
Cash Flow
In the last 12 months, operating cash flow was -$306.36 million and capital expenditures -$889,000, giving a free cash flow of -$307.25 million.
| Operating Cash Flow | -306.36M |
| Capital Expenditures | -889,000 |
| Depreciation & Amortization | 2.47M |
| Net Borrowing | n/a |
| Free Cash Flow | -307.25M |
| FCF Per Share | -$3.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.16% |
| Shareholder Yield | -4.16% |
| Earnings Yield | -6.19% |
| FCF Yield | -4.97% |
Analyst Forecast
The average price target for XENE is $80.93, which is 26.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $80.93 |
| Price Target Difference | 26.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 225.19% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 36.19 and a Piotroski F-Score of 2.
| Altman Z-Score | 36.19 |
| Piotroski F-Score | 2 |